Opexa Therapeutics (NASDAQ: ACER) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Earnings and Valuation

This table compares Opexa Therapeutics and AnaptysBio’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opexa Therapeutics $2.90 million 32.41 -$7.97 million ($5.75) -2.53
AnaptysBio $16.68 million 123.76 -$4.25 million N/A N/A

AnaptysBio has higher revenue and earnings than Opexa Therapeutics.

Institutional & Insider Ownership

0.3% of Opexa Therapeutics shares are held by institutional investors. Comparatively, 75.5% of AnaptysBio shares are held by institutional investors. 6.9% of Opexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Opexa Therapeutics and AnaptysBio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opexa Therapeutics N/A -108.02% -88.85%
AnaptysBio N/A -39.38% -24.95%

Analyst Recommendations

This is a summary of recent ratings for Opexa Therapeutics and AnaptysBio, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opexa Therapeutics 0 0 0 0 N/A
AnaptysBio 0 0 8 0 3.00

AnaptysBio has a consensus price target of $86.13, indicating a potential downside of 1.95%. Given AnaptysBio’s higher possible upside, analysts plainly believe AnaptysBio is more favorable than Opexa Therapeutics.

Summary

AnaptysBio beats Opexa Therapeutics on 8 of the 9 factors compared between the two stocks.

About Opexa Therapeutics

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

About AnaptysBio

AnaptysBio, Inc. is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company’s ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.